Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Currently, there is no consensus on best practices to prevent hemorrhagic cystitis (HC) in patients receiving posttransplant cyclophosphamide (PTCy). We retrospectively reviewed 194 patients undergoing their first hematopoietic cell transplant (HCT) who received PTCy from 2014 to 2018 to describe th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2021-10, Vol.56 (10), p.2464-2470
Hauptverfasser:	Mac, Stephanie, Ngo, Dat, Yang, Dongyun, Chen, Jason, Ali, Haris, Arslan, Shukaib, Dadwal, Sanjeet, Salhotra, Amandeep, Cao, Thai, Karras, Nicole, Aldoss, Ibrahim, Koller, Paul, Artz, Andrew, Aribi, Ahmed, Sandhu, Karamjeet, Pullarkat, Vinod, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Al Malki, Monzr M.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990 692/699/1541/1990 Best practice Cell Biology Complications and side effects Cyclophosphamide Cyclophosphamide - adverse effects Cystitis Cystitis - epidemiology Cystitis - etiology Diuresis Dosage Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Hemorrhage Hemorrhagic cystitis Humans Incidence Internal Medicine Medicine Medicine & Public Health Mesna - adverse effects Middle Aged Multivariate analysis Prevention Prophylaxis Public Health Retrospective Studies Risk analysis Risk factors Stem cell transplantation Stem Cells Transplantation Transplantation, Homologous Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!